Technical Analysis for PRPO - Precipio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 6.30 | -1.72% | -0.11 |
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | -1.72% | |
| Gapped Down | Weakness | -1.72% | |
| NR7 | Range Contraction | 0.64% | |
| NR7-2 | Range Contraction | 0.64% | |
| Narrow Range Bar | Range Contraction | 0.64% | |
| Lower Bollinger Band Walk | Weakness | 0.64% |
| Alert | Time |
|---|---|
| Gap Down Partially Closed | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| 10 DMA Resistance | 2 days ago |
| Down 3% | 2 days ago |
| Down 2 % | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 11/11/2024
Precipio, Inc. Description
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Biology Disease Natural Sciences Treatment Of Cancer Molecular Biology Genomics Molecular Diagnostics Analytical Services Laboratory Services Personalized Medicine Laboratory Techniques Polymerase Chain Reaction Pharmacogenomics Molecular Technologies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.7423 |
| 52 Week Low | 4.31 |
| Average Volume | 9,583 |
| 200-Day Moving Average | 6.06 |
| 50-Day Moving Average | 6.52 |
| 20-Day Moving Average | 6.57 |
| 10-Day Moving Average | 6.41 |
| Average True Range | 0.33 |
| RSI (14) | 45.05 |
| ADX | 22.79 |
| +DI | 13.91 |
| -DI | 18.57 |
| Chandelier Exit (Long, 3 ATRs) | 6.01 |
| Chandelier Exit (Short, 3 ATRs) | 7.00 |
| Upper Bollinger Bands | 7.03 |
| Lower Bollinger Band | 6.11 |
| Percent B (%b) | 0.21 |
| BandWidth | 14.02 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.041 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.47 | ||||
| Resistance 3 (R3) | 6.48 | 6.45 | 6.44 | ||
| Resistance 2 (R2) | 6.45 | 6.40 | 6.44 | 6.43 | |
| Resistance 1 (R1) | 6.37 | 6.38 | 6.36 | 6.36 | 6.42 |
| Pivot Point | 6.34 | 6.34 | 6.33 | 6.33 | 6.34 |
| Support 1 (S1) | 6.26 | 6.29 | 6.25 | 6.25 | 6.18 |
| Support 2 (S2) | 6.23 | 6.27 | 6.22 | 6.17 | |
| Support 3 (S3) | 6.15 | 6.23 | 6.16 | ||
| Support 4 (S4) | 6.14 |
